查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1509675

醫藥品受託製造的全球市場的評估:各類服務，各劑型，各終端用戶，各地區，機會，預測(2017年～2031年)

Pharmaceutical Contract Manufacturing Market Assessment, By Service, By Dosage Form, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5個工作天內

價格

全球藥品合約製造市場規模預計將從 2023 年的 2070.6 億美元增至 2031 年的 3576.3 億美元，預計 2024-2031 年的複合年增長率為 7.07%。製藥業的快速擴張、仿製藥投資的增加、技術進步、成功的併購等是市場的主要成長動力。

全球各地區市場的擴張得到了慢性病、殘疾和傳染病病例數量不斷增加的支持。根據世界衛生組織 (WHO) 估計，心血管疾病是導致死亡的主要原因之一，每年約導致 1,790 萬人死亡。此類慢性疾病的增加增加了對各種治療解決方案的需求，以有效治療和管理其症狀，為市場提供了利潤豐厚的成長機會。這是因為藥品生產過程需要專門的設施和設備，而建立藥品生產設施往往耗時且經濟負擔重。因此，公司依靠合約製藥公司來滿足對治療藥物不斷增長的需求。

製藥合約製造公司提供的廣泛優勢，例如節省時間、提高成本效率、提高靈活性和合規性優勢，也支持了市場成長。另一方面，增加合作夥伴關係和收購也支持市場擴張。 2024 年 6 月，Great Point Partners, LLC 收購了 Lyocontract GmbH。此次收購將有助於 Lyocontract 擴大其產品組合併擴大其全球足跡。 Great Point 的資本實力和 Lyocontract 的合約製造能力的結合將使兩家公司能夠提供高品質的產品。

醫藥產業擴張帶動市場需求

未來幾年製藥業的快速擴張預計將推動全球製藥合約製造市場的成長。根據歐洲製藥工業聯合會估計，2023年北美將佔全球藥品銷售額的53.3%，歐洲將佔22.7%。由於藥品合約製造有助於優化營運成本，預計這一增長將有助於擴大市場。對藥品的需求不斷增長，導致公司依賴合約製造公司提供靈活的測試、二級包裝組裝、製造和初級包裝方法。這為未來幾年的市場提供了有利的成長機會。

此外，重磅藥品和生物製品的到期日增加預計也將推動市場擴張。這些到期預計將增加對重磅藥物的仿製藥的需求，這預計將增加對合約藥品製造的需求，以滿足這種增加的需求。這是因為製藥公司專注於開發新療法，並且更願意將藥品生產外包給合約製造組織。另一方面，世界各地慢性病威脅的不斷上升也為市場創造了利潤豐厚的成長機會。慢性病的增加預計將增加對各種治療解決方案的需求，從而導致合約藥品製造的需求增加。

慢性病的增加支持市場擴張

由於世界不同地區的疾病負擔不斷增加，對治療各種慢性疾病的有效療法的需求不斷增加。根據美國癌症協會預測，2024年美國將新增2,001,140例癌症相關病例，611,720例死亡病例。癌症患者數量的增加將增加對癌症治療藥物的需求並支持市場成長。此外，加強各監管機構、研究機構和製藥公司之間的合作，以加速藥物開發進程並促進創新，同時確保病患安全，也預計將帶來機會。此外，多家公司正在投資合約開發和生產設施，以滿足癌症藥物不斷增長的需求。 2022 年 6 月，默克宣佈在美國威斯康辛州開設一座佔地 70,000 平方英尺的新工廠，將高活性藥物成分的產能提高一倍，以滿足日益增長的癌症治療需求。

本報告提供全球醫藥品受託製造市場相關調查分析，提供市場規模與預測，市場動態，主要企業的形勢及預測等資訊。

目錄

第1章 調查手法

第2章 計劃的範圍和定義

第3章 摘要整理

第4章 全球醫藥品受託製造市場預測(2017年～2031年)

  • 市場規模與預測
    • 金額
  • 各類服務
    • 醫藥品製造服務
    • 生物製藥製造服務
    • 醫藥品開發服務
  • 各劑型
    • 口服固態劑
    • 口服液劑
    • 液劑
    • 非口服
    • 其他
  • 各終端用戶
    • 大型製藥企業
    • 中小製藥企業
    • 學名藥企業
    • 其他
  • 各地區
    • 北美
    • 南美
    • 歐洲
    • 亞太地區
    • 中東·非洲
  • 市場佔有率:各企業(2023年)

第5章 全球醫藥品受託製造市場預測:各地區(2017年～2031年)

  • 北美
    • 市場規模與預測
    • 各類服務
    • 各劑型
    • 各終端用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 南美
    • 巴西
    • 阿根廷
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第6章 市場製圖(2023年)

  • 各類服務
  • 各劑型
  • 各終端用戶
  • 各地區

第7章 宏觀環境和產業結構

  • 供需分析
  • 進口出口分析
  • 價值鏈分析
  • PESTEL分析
  • 波特的五力分析

第8章 市場動態

  • 成長促進因素
  • 阻礙成長的要素(課題，阻礙因素)

第9章 法規結構和革新

  • 專利形勢
  • 法規當局的認證
  • 革新/新技術

第10章 主要企業的形勢

  • 市場領導者前五名公司的競爭矩陣
  • 市場領導者前五名公司的市場收益的分析(2023年)
  • 合併和收購/合資企業(如果適用)
  • SWOT分析(市場5企業)
  • 專利分析(如果適用)

第11章 價格分析

第12章 案例研究

第13章 主要企業預測

  • Thermo Fisher Scientific Inc.
  • Abbvie Inc.
  • Lonza Group Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Pfizer, Inc.
  • Evonik Industries AG
  • Dr. Reddy's Laboratories Ltd.
  • Jubilant Pharmova Limited
  • Recipharm AB

第14章 策略性推薦

第15章 本公司相關資料，免責聲明

Product Code: MX11556

Global pharmaceutical contract manufacturing market is projected to witness a CAGR of 7.07% during the forecast period 2024-2031F, growing from USD 207.06 billion in 2023 to USD 357.63 billion in 2031F. The rapid expansion of the pharmaceutical sector, increasing investments in generics, technological advancements, and successful mergers and acquisitions are some of the major drivers that are expected to aid the growth of the market.

The expansion of the market in various regions across the globe is supported by the rise in the cases of chronic diseases and disorders and infectious diseases as they propel the requirement for pharmaceutical products. According to estimates from the World Health Organization (WHO), cardiovascular diseases are one of the leading causes of death, killing approximately 17.9 million individuals every year. The augmentation of such chronic diseases will bolster the requirement for various therapeutic solutions in order to effectively treat and manage the conditions, thus providing lucrative growth opportunities to the market. This is because the drug production process requires specialized facilities and equipment, and the process of setting up a pharmaceutical production facility can often be time-consuming and economically draining. Therefore, various companies rely on pharmaceutical contract manufacturing companies to meet the growing demand for therapeutic drugs.

The growth of the market is also supported by the wide range of benefits offered by pharmaceutical contract manufacturers, including reduced time, cost efficiency, increased flexibility, and compliance benefits. Meanwhile, the increasing partnerships and acquisitions are also supporting the expansion of the market. In June 2024, Great Point Partners, LLC acquired Lyocontract GmbH. The acquisition will aid the latter in broadening their product offerings and expanding their global footprint. The capital resources of Great Point combined with the contract manufacturing capabilities of Lyocontract will allow both companies to deliver high-quality products.

Expansion of the Pharmaceutical Sector Boosts Market Demand

The rapid expansion of the pharmaceutical sector in the coming years is expected to bolster the global pharmaceutical contract manufacturing market growth. The European Federation of Pharmaceutical Industries and Association estimates that North America accounted for 53.3% of global pharmaceutical sales in 2023, and Europe accounted for 22.7% of the sales. This increase is expected to aid the expansion of the market as pharmaceutical contract manufacturing aids the optimization of operational expenses. Due to the rising demand for pharmaceutical products, various companies rely on contract manufacturing companies as they provide an agile approach for testing, assembling secondary packaging, manufacturing, and primary packaging. Thus, providing lucrative growth opportunities to the market in the coming years.

Additionally, the increasing expiration of blockbuster drugs and biologics is also expected to aid the expansion of the market. Due to this expiration, the demand for generics of blockbuster drugs is anticipated to rise, which in turn is expected to propel the demand for pharmaceutical contract manufacturing to meet this rising demand. This is because pharmaceutical companies are focused on developing novel therapeutic solutions and prefer outsourcing drug manufacturing to contract manufacturing organizations. Meanwhile, the growing threat of chronic diseases in different regions across the globe is also providing lucrative growth opportunities to the market. The increasing cases of chronic diseases are anticipated to bolster the requirement for various therapeutic solutions, which in turn is expected to augment the requirement for pharmaceutical contract manufacturing.

Increasing Prevalence of Chronic Diseases Supports Market Expansion

The rising requirement for effective therapies for treating various chronic diseases can be attributed to the growing burden of diseases in various regions across the globe. The American Cancer Society estimates that 2,001,140 new cases and 611,720 deaths related to cancer are expected to occur in 2024 in the United States. This increase in the number of cancer cases will augment the demand for oncology drugs, boosting the growth of the market. Furthermore, rising collaborations between various regulatory entities, research institutions, and pharmaceutical companies to expedite the drug development processes and foster innovation while ensuring the safety of the patients are also expected to offer lucrative growth opportunities to the market. Additionally, various companies are also investing in contract development and manufacturing facilities to address the rising demand for cancer therapies. In June 2022, Merck KGaA announced the opening of their new 70,000 square feet facility in Wisconsin, United States, to double the production capacity of their high-potency active pharmaceutical ingredients to meet the growing requirement of cancer therapies.

North America Expected to Account for Significant Market Share

The growth of the market in North America is supported by the rising requirement for generics, the expansion of the aging population, increasing cases of chronic diseases, and the strong presence of key market players in the region. The increasing prevalence of various chronic diseases and disorders, such as diabetes and cancer, in the region is bolstering the requirement for effective drugs for treating these conditions. According to estimates from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 29.7 million individuals of all ages, roughly 8.9% of the population, have been diagnosed with diabetes. The increasing cases of such conditions are propelling the requirement for effective drugs for their management and treatment, which, in turn, is augmenting the market demand.

Generic Pharmaceutical Companies are Expected to Witness Growth

The generic pharmaceutical companies are expected to witness significant growth in the coming years. This growth of the segment can be attributed to the expiration of branded drugs and the increasing requirement for generic drugs. The increasing requirement for generics can be attributed to the growing awareness of their potential to enhance healthcare accessibility by offering economically efficient alternatives to expensive biological therapies. According to estimates from the Association for Accessible Medicines (AAM), biosimilar and generic prescriptions account for 90% of the total prescriptions filled in the United States. Furthermore, the biosimilar and generic drugs generated USD 408 billion for the American healthcare system and its patients in 2022. This growth of biosimilar and generic drugs, is in turn, positively influencing the expansion of the market. Additionally, the rising prevalence of several genetic disorders, chronic diseases, and infectious diseases in various regions across the globe are propelling the requirement for safe and effective medications, thus bolstering the demand for pharmaceutical contract manufacturing as they aid in providing quality-assured products in a cost-efficient manner.

Future Market Scenario (2024-2031F)

According to the global pharmaceutical contract manufacturing market analysis, contract manufacturing is expected to play a significant role in the pharmaceutical industry in the coming years, and the integration of novel technologies, such as machine learning and artificial intelligence, is anticipated to aid in enhancing the operations of pharmaceutical contract manufacturing. The deployment of real-time monitoring solutions due to the advent of the Internet of Things (IoT) for ensuring that the quality is maintained during the production process and response is generated for any issues in a time-efficient manner is expected to enhance the reliability and efficiency of the supply chain in pharmaceutical contract manufacturing.

Key Players Landscape and Outlook

Successful mergers and acquisitions are expected to boost the global pharmaceutical contract manufacturing market size. In February 2024, Novo Holdings A/S and Catalent, Inc. announced that they have entered into a merger agreement, and Novo Holdings will be acquiring Catalent for USD 16.5 billion. Novo Holdings will be transferring Catalent's manufacturing sites to Novo Nordisk A/S to boost their efforts to meet the growing demand for their injectable obesity and semaglutide-based diabetes drugs Wegovy and Ozempic. The acquired sites are expected to aid the company's filling capacity from 2026. This investment is expected to aid Novo Nordisk in enhancing its key product offerings and providing premium manufacturing and development solutions to biotech and pharma customers.

The increase in investments by the key market players in drug production facilities is also expected to bolster the growth of the market. In May 2023, Thermo Fisher Scientific Inc. opened a drug production facility in Singapore. The facility is expected to support the company's general manufacturing and development services and the Singapore Economic Development Board (EDB). The sterile fill-finish facility contains an automated aseptic fill-finish line with advanced isolator technology for small and large-sized molecules and vaccines.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Pharmaceutical Contract Manufacturing Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. By Service
    • 4.2.1. Pharmaceutical Manufacturing Services
      • 4.2.1.1. Pharmaceutical FDF Manufacturing Services
      • 4.2.1.2. Pharmaceutical API Manufacturing Services
    • 4.2.2. Biologic Manufacturing Services
      • 4.2.2.1. Biologic FDF Manufacturing Services
      • 4.2.2.2. Biologic API Manufacturing Services
    • 4.2.3. Drug Development Services
  • 4.3. By Dosage Form
    • 4.3.1. Oral Solids
    • 4.3.2. Oral Liquid
    • 4.3.3. Emulsions
    • 4.3.4. Parenteral
    • 4.3.5. Others
  • 4.4. By End-user
    • 4.4.1. Big Pharmaceutical Companies
    • 4.4.2. Small and Mid-Sized Pharmaceutical Companies
    • 4.4.3. Generic Pharmaceutical Companies
    • 4.4.4. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. South America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East & Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Pharmaceutical Contract Manufacturing Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
    • 5.1.2. By Service
      • 5.1.2.1. Pharmaceutical Manufacturing Services
        • 5.1.2.1.1. Pharmaceutical FDF Manufacturing Services
        • 5.1.2.1.2. Pharmaceutical API Manufacturing Services
      • 5.1.2.2. Biologic Manufacturing Services
        • 5.1.2.2.1. Biologic FDF Manufacturing Services
        • 5.1.2.2.2. Biologic API Manufacturing Services
      • 5.1.2.3. Drug Development Services
    • 5.1.3. By Dosage Form
      • 5.1.3.1. Oral Solids
      • 5.1.3.2. Oral Liquid
      • 5.1.3.3. Emulsions
      • 5.1.3.4. Parenteral
      • 5.1.3.5. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Big Pharmaceutical Companies
      • 5.1.4.2. Small and Mid-Sized Pharmaceutical Companies
      • 5.1.4.3. Generic Pharmaceutical Companies
      • 5.1.4.4. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
        • 5.1.5.1.1. By Value
      • 5.1.5.2. By Service
        • 5.1.5.2.1. Pharmaceutical Manufacturing Services
          • 5.1.5.2.1.1. Pharmaceutical FDF Manufacturing Services
          • 5.1.5.2.1.2. Pharmaceutical API Manufacturing Services
        • 5.1.5.2.2. Biologic Manufacturing Services
          • 5.1.5.2.2.1. Biologic FDF Manufacturing Services
          • 5.1.5.2.2.2. Biologic API Manufacturing Services
        • 5.1.5.2.3. Drug Development Services
      • 5.1.5.3. By Dosage Form
        • 5.1.5.3.1. Oral Solids
        • 5.1.5.3.2. Oral Liquid
        • 5.1.5.3.3. Emulsions
        • 5.1.5.3.4. Parenteral
        • 5.1.5.3.5. Others
      • 5.1.5.4. By End-user
        • 5.1.5.4.1. Big Pharmaceutical Companies
        • 5.1.5.4.2. Small and Mid-Sized Pharmaceutical Companies
        • 5.1.5.4.3. Generic Pharmaceutical Companies
        • 5.1.5.4.4. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Service
  • 6.2. By Dosage Form
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Abbvie Inc.
  • 13.3. Lonza Group Ltd.
  • 13.4. Boehringer Ingelheim International GmbH
  • 13.5. Catalent, Inc.
  • 13.6. Pfizer, Inc.
  • 13.7. Evonik Industries AG
  • 13.8. Dr. Reddy's Laboratories Ltd.
  • 13.9. Jubilant Pharmova Limited
  • 13.10. Recipharm AB

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 3. Global Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 4. Global Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 5. Global Pharmaceutical Contract Manufacturing Market Share (%), By Region, 2017-2031F
  • Figure 6. North America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 7. North America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 8. North America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 9. North America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 10. North America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 11. United States Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 12. United States Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 13. United States Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 14. United States Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 15. Canada Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 17. Canada Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 18. Canada Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 19. Mexico Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 20. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 21. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 22. Mexico Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 23. Europe Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 24. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 25. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 26. Europe Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 27. Europe Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 28. Germany Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 29. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 30. Germany Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 31. Germany Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 32. France Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 33. France Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 34. France Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 35. France Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 36. Italy Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 37. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 38. Italy Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 39. Italy Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 40. United Kingdom Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 42. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 43. United Kingdom Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 44. Russia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 45. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 46. Russia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 47. Russia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 48. Netherlands Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 49. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 50. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 51. Netherlands Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 52. Spain Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 54. Spain Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 55. Spain Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 56. Turkey Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 57. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 58. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 59. Turkey Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 60. Poland Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 62. Poland Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 63. Poland Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 64. South America Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. South America Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 66. South America Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 67. South America Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 68. South America Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 69. Brazil Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 70. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 71. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 72. Brazil Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 73. Argentina Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 74. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 75. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 76. Argentina Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 77. Asia-Pacific Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 78. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 79. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 80. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 81. Asia-Pacific Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 82. India Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. India Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 84. India Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 85. India Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 86. China Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 87. China Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 88. China Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 89. China Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 90. Japan Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 91. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 92. Japan Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 93. Japan Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 94. Australia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 96. Australia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 97. Australia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 98. Vietnam Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 99. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 100. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 101. Vietnam Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 102. South Korea Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 104. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 105. South Korea Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 106. Indonesia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 107. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 108. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 109. Indonesia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 110. Philippines Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 111. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 112. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 113. Philippines Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 114. Middle East & Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 115. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 116. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 117. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 118. Middle East & Africa Pharmaceutical Contract Manufacturing Market Share (%), By Country, 2017-2031F
  • Figure 119. Saudi Arabia Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 120. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 121. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 122. Saudi Arabia Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 123. UAE Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 124. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 125. UAE Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 126. UAE Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 127. South Africa Pharmaceutical Contract Manufacturing Market, By Value, In USD Billion, 2017-2031F
  • Figure 128. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Service, 2017-2031F
  • Figure 129. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By Dosage Form, 2017-2031F
  • Figure 130. South Africa Pharmaceutical Contract Manufacturing Market Share (%), By End-user, 2017-2031F
  • Figure 131. By Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 132. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023